Pharmaceutical Executive
Pharmaceutical Executive: October 2026
Volume: 46
Issue: 8
Pharmaceutical Executive: September 2026
Volume: 46
Issue: 7
Pharmaceutical Executive: August 2026
Volume: 46
Issue: 6
Pharmaceutical Executive: June 2026
Volume: 46
Issue: 5
Pharmaceutical Executive: May 2026
Volume: 46
Issue: 4
Pharmaceutical Executive: April 2026
Volume: 46
Issue: 3
Pharmaceutical Executive: March 2026
Volume: 46
Issue: 2
Pharmaceutical Executive: February 2026
Volume: 46
Issue: 1
Pharmaceutical Executive: December 2025
Volume: 45
Issue: 9
Pharmaceutical Executive: October 2025
Volume: 45
Issue: 8
Pharmaceutical Executive: September 2025
Volume: 45
Issue: 7
Pharmaceutical Executive: August 2025
Volume: 45
Issue: 6
Pharmaceutical Executive: June 2025
Volume: 45
Issue: 5
Pharmaceutical Executive: May 2025
Volume: 45
Issue: 4
Pharmaceutical Executive: April 2025
Volume: 45
Issue: 3
Pharmaceutical Executive: March 2025
Volume: 45
Issue: 2
Pharmaceutical Executive: February 2025
Volume: 45
Issue: 1
Pharmaceutical Executive: December 2024
Volume: 44
Issue: 12
Pharmaceutical Executive: November 2024
Volume: 44
Issue: 11
Pharmaceutical Executive: October 2024
Volume: 44
Issue: 10
Pharmaceutical Executive: September 2024
Volume: 44
Issue: 9
Pharmaceutical Executive: July/August 2024
Volume: 44
Issue: 7/8
Pharmaceutical Executive: June 2024
Volume: 44
Issue: 6
Pharmaceutical Executive: May 2024
Volume: 44
Issue: 5
Pharmaceutical Executive: April 2024
Volume: 44
Issue: 4
Pharmaceutical Executive: March 2024
Volume: 44
Issue: 3
Pharmaceutical Executive: February 2024
Volume: 44
Issue: 1
Pharmaceutical Executive: December 2023
Volume: 43
Issue: 12
Pharmaceutical Executive: November 2023
Volume: 43
Issue: 11
Pharmaceutical Executive: October 2023
Volume: 43
Issue: 10
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
2
The Importance of Reframing COVID-19 as a Preventable Event
3
FDA Extends Talzenna-Xtandi to Hormone-Sensitive Prostate Cancer
4
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
5